The most prevalent metabolic disorders are diabetes mellitus, obesity, dyslipidemia,
osteoporosis and metabolic syndrome, which are developed when normal metabolic …

Blood glucose control, for example, in diabetes mellitus or severe illness, requires strict
adherence to a protocol of food, insulin administration and exercise personalized to each …

Over the years, natural products have shown success as antidiabetics in in vitro, in vivo
studies and clinical trials. Because natural product-derived drugs are more affordable and …

A meta-analysis was conducted to assess the clinical efficacy and safety of dulaglutide in
patients with type 2 diabetes mellitus (T2DM). Medline, Embase, Cochrane Library and …

Introduction: Type 2 diabetes mellitus (T2DM) is a major metabolic, multi-causal and
heterogeneous disorder which causes significant morbidity and mortality with considerable …

Pharmacological treatment of type 2 diabetes has been enriched during recent years, with
the launch of incretin therapies targeting glucagon-like peptide-1 (GLP-1). Such medications …

Evidence of a neurophysiologic mechanism that involves hormones from adipocytes,
pancreatic islet cells, and the gastrointestinal tract implicated in both obesity and diabetes …

Background/objectives Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is
increasingly used in obese or overweight patients with diabetes. However, its safety profile …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated benefits for
patients with type 2 diabetes including A1C reduction and weight loss with minimal risk of …

Aims To investigate the antidiabetic actions of three dogfish glucagon peptide analogues
[known glucagon‐like peptide‐1 and glucagon receptor co‐agonists] after chronic …